Form 4: Cigna CFO Dennison Reports Equity Awards

Cigna Group's EVP and CFO, Ann M. Dennison, reported the acquisition of restricted stock and employee stock options, alongside a disposition of shares for tax purposes.

Summary

• Ann M. Dennison, Executive Vice President and Chief Financial Officer of Cigna Group (CI), reported changes in her beneficial ownership of company securities.
• Acquired 5,234 shares of Common Stock, $.01 Par Value, as restricted shares on February 27, 2026, with a transaction price of $0.
• Disposed of 409 shares of Common Stock, $.01 Par Value, on February 27, 2026, at a price of $287.55 per share to satisfy tax obligations upon the vesting of restricted shares.
• Acquired 8,066 Employee Stock Options (Right to Buy) on February 27, 2026, with an exercise price of $287.5475.
• Following these transactions, beneficial ownership of non-derivative Common Stock is 7,745 shares.
• Beneficial ownership of derivative Employee Stock Options is 8,066 options.
• The restricted shares and employee stock options vest in three equal annual installments, commencing March 1, 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive, routine filing. It reflects standard executive compensation practices and aligns management incentives with shareholder value, without indicating any significant new developments or concerns.

Positives

• The acquisition of 5,234 restricted shares and 8,066 employee stock options indicates continued alignment of executive incentives with shareholder interests.
• The grants represent a component of executive compensation, reflecting ongoing commitment to the company.

Negatives

• The disposition of 409 shares was solely to cover tax obligations related to vesting restricted shares, which is a standard and expected event for equity compensation.

Future Outlook

The filing primarily details past and scheduled future vesting events for executive compensation, rather than providing a broader future outlook for the company's performance.

Industry Context

StockSavvy.ai notes that the grant of restricted stock and stock options to a senior executive like the CFO is a standard practice in the healthcare and insurance industry. This form of compensation is designed to align management's long-term interests with those of shareholders, encouraging sustained performance and retention. Such grants are common across large-cap companies, including Cigna's peers like UnitedHealth Group (UNH) and Elevance Health (ELV), which frequently utilize similar equity-based incentive programs.

Comparison to Industry Standards

• The use of restricted stock and employee stock options for executive compensation aligns with common practices observed in major U.S. public companies, particularly within the healthcare and insurance sectors.
• Comparable companies such as UnitedHealth Group and Elevance Health regularly grant similar equity awards to their senior executives as part of their total compensation packages, emphasizing long-term performance and retention.
• The vesting schedule of three equal annual installments is a typical structure designed to encourage sustained executive performance over several years, a standard benchmark in corporate governance for executive incentives.

Stakeholder Impact

• Shareholders: The equity grants align the CFO's financial interests with long-term shareholder value creation, potentially fostering sustained performance.
• Employees: No direct impact on general employees is indicated by this filing, though executive compensation practices can indirectly influence overall company culture and compensation philosophy.

Next Steps

• The restricted shares will vest in three equal annual installments beginning March 1, 2027.
• The employee stock options will vest in three equal annual installments beginning March 1, 2027.

Key Dates

Keywords

Cigna, CI, Form 4, Insider Transaction, Executive Compensation, Restricted Stock, Stock Options, Equity Awards